Overcome the challenges of PMS2 variant calling with Devyser LynchFAP – our new NGS solution
Devyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
News | October 29, 2024
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoringNews | October 28, 2024
Devyser Compact achieves Class III approval in China
Devyser launches two new genetic testing solutions for hereditary cancer
Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA...
Simplify your lab workflow with single-tube NGS library preparation method
As a lab manager, you know the importance of streamlining workflows to maximize productivity and...
NGS identification of both male and female cancer risks
Do you know a man who has participated at least once in “Movember”? Every year, thousands of men...